6-K
Alpha Tau Medical Ltd. (DRTS)
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM6-K
REPORTOF FOREIGN PRIVATE ISSUER
PURSUANTTO SECTION 13A-16 OR 15D-16
UNDERTHE SECURITIES EXCHANGE ACT OF 1934
Forthe month of May 2025
CommissionFile Number: 001-41316
AlphaTau Medical Ltd.
(ExactName of Registrant as Specified in Its Charter)
KiryatHaMada St. 5
Jerusalem,Israel 9777605
+972(3) 577-4115
(Addressof principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
On May 6, 2025, Alpha Tau Medical Ltd. (the “Company”) issued a press release titled “Alpha Tau to Participate in May Investor Conferences.” A copy of this press release is attached to this Form 6-K as Exhibit 99.1.
The information in this Report on Form 6-K, including in Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
1
EXHIBIT INDEX
| Exhibit No. | Description |
|---|---|
| 99.1 | Press release dated May 6, 2025. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Alpha Tau Medical Ltd. | ||
|---|---|---|
| Date: May 6, 2025 | By: | /s/ Uzi Sofer |
| Uzi Sofer | ||
| Chief Executive Officer |
3
Exhibit 99.1
Alpha Tau to Participatein May Investor Conferences
JERUSALEM, May 6, 2025 -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT^®^, today announced that CFO Raphi Levy will presentation in the following investor conferences in May 2025.
| Event: | H.C. Wainwright 3rd Annual BioConnect Investor Conference |
|---|---|
| Format: | Fireside Chat |
| Date: | May 20, 2025 |
| Time: | 3:30 – 4:00PM ET |
| Location: | New York, NY |
| Event: | Lytham Partners Spring 2025 Investor Conference |
| --- | --- |
| Format: | 1x1 Meetings |
| Date: | May 29, 2025 |
| Location: | Virtual |
Mr. Levy will be available for 1x1 investor meetings at both conferences. Please reach out to your H.C. Wainwright and Lytham Partners representatives to schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT^®^
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact: